<DOC>
	<DOCNO>NCT01891123</DOCNO>
	<brief_summary>As cytotoxic agent , DTX PTX narrow therapeutic window . BSA dose lead great inter-individual PK variability , major contributor severe toxicity , especially East-Asian population . DTX exposures measure area plasma concentration-time curve ( AUC ) , PTX exposures measure time plasma concentration 0.05 µmol/L ( TC &gt; 0.05 ) , biologic effect associate PK parameter DTX PTX , respectively , could positively predict related toxicity neutropenia , peripheral neuropathy , etc . So , conduct randomized clinical trial compare effect related toxicity efficacy PK-guided dosing strategy BSA dosing strategy .</brief_summary>
	<brief_title>Explore Individual Treatment Docetaxel Paclitaxel NSCLC , NPC BRC PK-guided Dosing Strategy</brief_title>
	<detailed_description>3 population include : advanced NSCLC patient receive single-agent docetaxel regimen palliative chemotherapy without restriction line ; NPC patient receive paclitaxel carboplatin doublet regimen whether induction chemotherapy local advance patient palliative chemotherapy metastatic patient ; BRC patient receive single-agent docetaxel regimen 4 cycle adriamycin cyclophosphamide adjuvant chemotherapy . Patients randomly assign BSA-based dose group pharmacokinetically-guided dose group . In BSA-based dosing group , NPC patient receive paclitaxel ( 175mg/m2 ) carboplatin ( AUC=5 ) treatment , NSCLC BRC patient receive docetaxel ( 75mg/m2 ) treatment , 3-weekly 6 cycle . BSA group PK-guided group start dose . DTX exposure ( AUC ) PTX exposure ( TC &gt; 0.05 ) calculate publish PK model establish limited sampling strategy . Dose subsequent cycle PK-guided group patient calculate base previous cycle PK result , accord optimal target algorithm . The optimal target DTX exposure 2.5 - 3.7 µg•h/mL . Dose reduction permit arm accord instruction . The study power 80 % detect 23 % reduction grade &gt; 3 neutropenia PK-guided arm DTX sub-study NSCLC . A sample size 100 NSCLC patient estimate use Fisher 's exact test provide 5 % two-sided alpha significance level observe decrease hematological toxicity power 0.8 . This base report toxicity rate 85 % dose 75mg/m2 63 % 60mg/m2 . Objective response rate evaluate image examination ( CT MR scan ) every 2 cycle . Toxicities evaluate patient ' diary toxicity report physician 's evaluation day 10 day 21 every cycle . Blood sample collect every cycle . And survival information collect clinic telephone follow-up . Research Hypothesis : 1 . The concentration variability dose BSA , limitation BSA- MTD-based dosing . 2 . Verify paclitaxel TC &gt; 0.05 docetaxel AUC relevant predictor related toxicity clinical outcome . 3 . Verify feasibility dose algorithm base paclitaxel TC &gt; 0.05 docetaxel AUC , quantify effect reduce toxicity improve Effectiveness . 4 . The effect use dose modification administration G-CSF base toxicity determine paclitaxel TC &gt; 0.05 docetaxel AUC measurement . 5 . Prove ability PK-guided dosing strategy reduce DTX PTX relate hematologic non-hematologic toxicity , effect treatment efficacy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nose Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Confirmed pathology advance non small cell lung cancer , suitable paclitaxel docetaxel chemotherapy ( clinical stage IV accord 2009 IASLC stag recurrent NSCLC ; receive palliative chemotherapy independent line ) ECOG PS score : 0 2 point Survival expect 3 month Bone marrow reserve function good , function organ ( liver kidney ) good , satisfy condition implementation chemotherapy . Sign inform consent form Compliance good , follow , willing comply requirement study Physical status score ( ECOG ) great 2 organic disease；Severely active infection；Organ transplantation immune therapy；Ca n't complete four six cycle chemotherapy Bone marrow , liver kidney dysfunction , clinical doctor identify intolerance chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>plasma drug concentration</keyword>
	<keyword>Nasopharygeal carcinoma</keyword>
</DOC>